Effect of short-term synbiotic treatment on plasma p-cresol levels in patients with chronic renal failure: A randomized clinical trial

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 24, Issue 9, 2014, Pages 1043-1049

  Guida, B ^a   Germano R ^a   Trio, R ^a   Russo, D ^a   Memoli, B ^a   Grumetto, L ^a   Barbato, F ^a   Cataldi, M ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Chronic kidney disease; P cresol; Synbiotic

Indexed keywords

PARA CRESOL; SYNBIOTIC AGENT; 4-CRESOL; CRESOL;

ANTHROPOMETRY; ARTICLE; BLOOD CHEMISTRY; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; GASTROINTESTINAL SYMPTOM; HUMAN; IN VITRO STUDY; INTESTINE FLORA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; AGED; BLOOD; FEMALE; GLOMERULUS FILTRATION RATE; INTESTINE; KIDNEY FAILURE, CHRONIC; MALE; MICROBIOLOGY; MIDDLE AGED; PILOT STUDY;

AGED; CRESOLS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INTESTINES; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PILOT PROJECTS; SYNBIOTICS;

EID: 84929045778     PISSN: 09394753     EISSN: 15903729     Source Type: Journal    
DOI: 10.1016/j.numecd.2014.04.007     Document Type: Article

References (30)

1. Strid H., Simrén M., Stotzer P.O., Ringström G., Abrahamsson H., et al. Patients with chronic renal failure have abnormal small intestinal motility and a high prevalence of small intestinal bacterial overgrowth. Digestion 2003, 67:129-137.
2. Vaziri N.D., Wong J., Pahl M., Piceno Y.M., Yuan J., et al. Chronic kidney disease alters intestinal microbial flora. Kidney Int 2013, 83:308-315.
3. Strid H., Simrén M., Johansson A.C., Svedlund J., Samuelsson O., et al. The prevalence of gastrointestinal symptoms in patients with chronic renal failure is increased and associated with impaired psychological general well-being. Nephrol Dial Transpl 2002, 17:1434-1439.
4. Schreiner G., Maher J. Biochemistry of uremia. Uremia 1960, 55-85. Charles Thomas, Springfield, MA.
5. Meijers B.K., Bammens B., De Moor B., Verbeke K., Vanrenterghem Y., et al. Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int 2008, 73:1174-1180.
6. Meijers B.K., Claes K., Bammens B., de Loor H., Viaene L., et al. P-cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol 2010, 5:1182-1189.
7. Vanholder R., Bammens B., de Loor H., Glorieux G., Meijers B., et al. Warning: the unfortunate end of p-cresol as a uraemic toxin. Nephrol Dial Transpl 2011, 26:1464-1467.
8. Food and Agriculture Organization and World Health Organization: Report of a joint FAO/WHO expert consultation on evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria 2001.
9. Gibson G.R., Scott K.P., Rastall R.A., Tuohy K.M., Hotchkiss A., et al. Dietary prebiotics: current status and new definition. Food Sci Technol Bull 2010, 7:1-19.
10. Almansa C., Agrawal A., Houghton L.A. Intestinal microbiota. Pathophysiology and translation to probiotic use in patients with irritable bowel syndrome. Expert Rev Gastroenterol Hepatol 2012, 6:383-398.
11. Hungin A.P., Mulligan C., Pot B., Whorwell P., Agréus L., et al. Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - an evidence-based international guide. Aliment Pharmacol Ther 2013, 8:864-886.
12. Guida B., Cataldi M., Maresca I.D., Germanò R., Trio R., et al. Dietary intake as a link between obesity, systemic inflammation, and the assumption of multiple cardiovascular and antidiabetic drugs in renal transplant recipients. Biomed Res Int 2013, 2013:363728.
13. Guida B., Napoleone A., Trio R., Nastasi A., Balato N., et al. Energy-restricted, n-3 polyunsaturated fatty acids-rich diet improves the clinical response to immuno-modulating drugs in obese patients with plaque-type psoriasis: a randomized control clinical trial. Clin Nutr 2014, 33:399-405.
14. Nakabayashi I., Nakamura M., Kawakami K., Ohta T., Kato I., et al. Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients: a preliminary study. Nephrol Dial Transpl 2011, 26:1094-1098.
15. Guida B., Cataldi M., Riccio E., Grumetto L., Pota A., et al. Plasma p-cresol lowering effect of sevelamer in peritoneal dialysis patients: evidence from a cross-sectional observational study. PLoS One 2013, 8:e73558.
16. Lin C.J., Chen H.H., Pan C.F., Chuang C.K., Wang T.J., et al. P-Cresylsulfate and indoxyl sulfate level at different stages of chronic kidney disease. J Clin Lab Anal 2011, 25:191-197.
17. Vitetta L., Gobe G. Uremia and chronic kidney disease: the role of the gut microflora and therapies with pro- and prebiotics. Mol Nutr Food Res 2013, 57:824-832.
18. Saulnier D.M., Spinler J.K., Gibson G.R., Versalovic J. Mechanisms of probiosis and prebiosis: considerations for enhanced functional foods. Curr Opin Biotechnol 2009, 20:135-141.
19. Roberfroid M.B. Prebiotics: preferential substrates for specific germs?. Am J Clin Nutr 2001, 73(Suppl.):406S-409S.
20. De Preter V., Vanhoutte T., Huys G., Swings J., De Vuyst L., et al. Effects of Lactobacillus casei Shirota. Bifidobacterium breve, and oligofructose-enriched inulin on colonic nitrogen-protein metabolism in healthy humans. Am J Physiol Gastrointest Liver Physiol 2007, 292:G358-G368.
21. Rossi M., Klein K., Johnson D.W., Campbell K.L. Pre-, pro-, and synbiotics: do they have a role in reducing uremic toxins? A systematic review and meta-analysis. Int J Nephrol 2012, 2012:673631.
22. Wu I.W., Hsu K.H., Lee C.C., Sun C.Y., Hsu H.J., et al. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transpl 2011, 26:938-947.
23. Bammens B., Evenepoel P., Keuleers H., Verbeke K., Vanrenterghem Y. Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int 2006, 69:1081-1087.
24. Cerini C., Dou L., Anfosso F., Sabatier F., Moal V., et al. p-cresol, a uremic retention solute alters the endothelial barrier function in vitro. Thromb Haemost 2004, 92:140-150.
25. Schepers E., Meert N., Glorieux G., Goeman J., Van der Eycken J., et al. P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transpl 2007, 22:592-596.
26. Niwa T., Ise M., Miyazaki T., Meada K. Suppressive effect of an oral sorbent on the accumulation of p-cresol in the serum of experimental uremic rats. Nephron 1993, 65:82-87.
27. Simrén M., Barbara G., Flint H.J., Spiegel B.M., Spiller R.C., et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 2013, 62:159-176.
28. Bonnema A.L., Kolberg L.W., Thomas W., Slavin J.L. Gastrointestinal tolerance of chicory inulin products. J Am Diet Assoc 2010, 110:865-868.
29. Sairanen U., Piirainen L., Gråsten S., Tompuri T., Mättö J., et al. The effect of probiotic fermented milk and inulin on the functions and microecology of the intestine. J Dairy Res 2007, 74:367-373.
30. Ranganathan N., Friedman E.A., Tam P., Rao V., Ranganathan P., et al. Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: a 6-month pilot scale trial in Canada. Curr Med Res Opin 2009, 25(8):1919-1930.